Thioaptamer-conjugated CD44-targeted delivery system for the treatment of breast cancer in vitro and in vivo

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5–29
   PubMed Web of Science ®Google Scholar
• Shen H, Mittal V, Ferrari M, Chang J. Delivery of gene silencing agents for breast cancer therapy. Breast Cancer Res 2013;15:205. doi: 10.1186/bcr3413
   PubMed Web of Science ®Google Scholar
• Munagala R, Aqil F, Gupta RC. Promising molecular targeted therapies in breast cancer. Indian J Pharmacol 2011;43:236–45
   PubMed Web of Science ®Google Scholar
• Escudero-Abarca BI, Suh SH, Moore MD, et al. Selection, characterization and application of nucleic acid aptamers for the capture and detection of human norovirus strains. PLoS One 2014;9:e106805
   Google Scholar
• Rozenblum GT, Kaufman T, Vitullo AD. Myelin basic protein and a multiple sclerosis-related MBP-peptide bind to oligonucleotides. Mol Ther Nucleic Acids 2014;3:e192
   Google Scholar
• Ding F, Guo S, Xie M, et al. Diagnostic applications of gastric carcinoma cell aptamers in vitro and in vivo. Talanta 2015;134:30–6
   PubMed Web of Science ®Google Scholar
• Kaur G, Roy I. Therapeutic applications of aptamers. Expert Opin Invest Drugs 2008;17:43–60
   PubMed Web of Science ®Google Scholar
• Kong HY, Byun J. Nucleic acid aptamers: new methods for selection, stabilization, and application in biomedical science. Biomol Ther (Seoul) 2013;21:423–34
   PubMed Web of Science ®Google Scholar
• Pendergrast PS, Marsh HN, Grate D, et al. Nucleic acid aptamers for target validation and therapeutic applications. J Biomol Technol 2005;16:224–34
   PubMedGoogle Scholar
• Somasunderam A, Thiviyanathan V, Tanaka T, et al. Combinatorial selection of DNA thioaptamers targeted to the HA binding domain of human CD44. Biochemistry 2010;49:9106–12
   PubMed Web of Science ®Google Scholar
• Peach RJ, Hollenbaugh D, Stamenkovic I, Aruffo A. Identification of hyaluronic acid binding sites in the extracellular domain of CD44. J Cell Biol 1993;122:257–64
   PubMed Web of Science ®Google Scholar
• Anand MT, Kumar S. CD44: a key player in breast cancer. Indian J Cancer 2014;51:247–50
   PubMed Web of Science ®Google Scholar
• Lila MA, Siew JS, Zakaria H, et al. Cell targeting in anti-cancer gene therapy. Malay J Med Sci 2004;11:9–23
   PubMedGoogle Scholar
• Louderbough JM, Schroeder JA. Understanding the dual nature of CD44 in breast cancer progression. Mol Cancer Res 2011;9:1573–86
   PubMed Web of Science ®Google Scholar
• Leth-Larsen R, Terp MG, Christensen AG, et al. Functional heterogeneity within the CD44 high human breast cancer stem cell-like compartment reveals a gene signature predictive of distant metastasis. Mol Med 2012;18:1109–21
   PubMed Web of Science ®Google Scholar
• Shirure VS, Liu T, Delgadillo LF, et al. CD44 variant isoforms expressed by breast cancer cells are functional E-selectin ligands under flow conditions. Am J Physiol Cell Physiol 2015;308:C68–78
   Google Scholar
• Yu CC, Tsai LL, Wang ML, et al. miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer. Cancer Res 2013;73:3425–40
   PubMed Web of Science ®Google Scholar
• Medimegh I, Omrane I, Privat M, et al. MicroRNAs expression in triple negative vs non triple negative breast cancer in Tunisia: interaction with clinical outcome. PLoS One 2014;9:e111877
   PubMed Web of Science ®Google Scholar
• Yang F, Zhang W, Shen Y, Guan X. Identification of dysregulated microRNAs in triple-negative breast cancer (Review). Int J Oncol 2015;46:927–32
   PubMed Web of Science ®Google Scholar
• Wu X, Tai Z, Zhu Q, et al. Study on the prostate cancer-targeting mechanism of aptamer-modified nanoparticles and their potential anticancer effect in vivo. Int J Nanomedicine 2014;9:5431–40
   PubMed Web of Science ®Google Scholar
• Liu J, Shapiro JI. Endocytosis and signal transduction: basic science update. Biol Res Nurs 2003;5:117–28
   PubMedGoogle Scholar
• Kim HR, Gil S, Andrieux K, et al. Low-density lipoprotein receptor-mediated endocytosis of PEGylated nanoparticles in rat brain endothelial cells. Cell Mol Life Sci 2007;64:356–64
   PubMed Web of Science ®Google Scholar
• Visser CC, Stevanovic S, Heleen Voorwinden L, et al. Validation of the transferrin receptor for drug targeting to brain capillary endothelial cells in vitro. J Drug Target 2004;12:145–50
   PubMed Web of Science ®Google Scholar
• Kim SJ, Shin JY, Lee KD, et al. MicroRNA let-7a suppresses breast cancer cell migration and invasion through downregulation of C-C chemokine receptor type 7. Breast Cancer Res 2012;14:R14
   PubMed Web of Science ®Google Scholar
• Xin H, Jiang X, Gu J, et al. Angiopep-conjugated poly(ethylene glycol)-co-poly(epsilon-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. Biomaterials 2011;32:4293–305
   PubMed Web of Science ®Google Scholar
• Li YT, Chua MJ, Kunnath AP, Chowdhury EH. Reversing multidrug resistance in breast cancer cells by silencing ABC transporter genes with nanoparticle-facilitated delivery of target siRNAs. Int J Nanomedicine 2012;7:2473–81
   PubMedGoogle Scholar
• Zuo L, Li L, Wang Q, et al. Mammaglobin as a potential molecular target for breast cancer drug delivery. Cancer Cell Int 2009;9:8. doi: 10.1186/1475-2867-9-8
   PubMed Web of Science ®Google Scholar